Friday Lecture Series

Dissecting the BCL-2 Family Interaction Network with Stapled Peptides:

Mechanistic Insights and Pharmacologic Opportunities

Loren Walensky, M.D., Ph.D., assistant professor, department of pediatrics, Harvard Medical School;

assistant professor, pediatric oncology, Dana-Farber Cancer Institute

May 6, 2011

3:45 p.m.-5:00 p.m. (Refreshments, 3:15 p.m., Abby Lounge)

Caspary Auditorium

Braun, C. R., J. Mintseris, E. Gavathiotis, G. H. Bird, S. P. Gygi, and L. D. Walensky. 2010. Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome. Chemistry and Biology 17, (12): 1325-1333

Kyoung, J. O., S. Barbuto, K. Pitter, J. Morash, L. D. Walensky, and S. J. Korsmeyer. 2006. A membrane-targeted BID BCL-2 homology 3 peptide is sufficient for high potency activation of BAX in vitro. Journal of Biological Chemistry 281, (48): 36999-37008

Letai, A., M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler, and S. J. Korsmeyer. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, (3): 183-192

Parra, M., P. Gascard, L. D. Walensky, J. A. Gimm, S. Blackshaw, N. Chan, Y. Takakuwa, et al. 2000. Molecular and functional characterization of protein 4.1B, a novel member of the protein 4.1 family with high level, focal expression in brain. Journal of Biological Chemistry 275, (5): 3247-3255

Walensky, L. D. 2006. BCL-2 in the crosshairs: Tipping the balance of life and death. Cell death and differentiation 13, (8): 1339-1350